First Eagle Investment Management LLC Sells 72,500 Shares of AngioDynamics, Inc. $ANGO

First Eagle Investment Management LLC lowered its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 19.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 305,335 shares of the medical instruments supplier’s stock after selling 72,500 shares during the period. First Eagle Investment Management LLC owned 0.75% of AngioDynamics worth $3,029,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Cerity Partners LLC raised its stake in shares of AngioDynamics by 22.0% during the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 2,333 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of AngioDynamics during the 1st quarter worth about $139,000. Fox Run Management L.L.C. acquired a new stake in shares of AngioDynamics in the 1st quarter valued at approximately $145,000. Y Intercept Hong Kong Ltd bought a new stake in shares of AngioDynamics in the 1st quarter valued at about $213,000. Finally, Bailard Inc. bought a new stake in AngioDynamics in the first quarter valued at approximately $241,000. Institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Lake Street Capital initiated coverage on shares of AngioDynamics in a report on Wednesday, July 16th. They set a “buy” rating and a $24.00 target price for the company. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group lifted their price target on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Trading Up 2.5%

Shares of ANGO stock opened at $12.02 on Friday. The stock has a market cap of $495.22 million, a P/E ratio of -15.41 and a beta of 0.74. The stock has a 50 day simple moving average of $11.28 and a 200 day simple moving average of $10.14. AngioDynamics, Inc. has a 1 year low of $6.63 and a 1 year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company’s revenue was up 12.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Insider Transactions at AngioDynamics

In other news, SVP Lawrence T. Weiss acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The stock was acquired at an average price of $11.81 per share, with a total value of $118,100.00. Following the completion of the transaction, the senior vice president directly owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This trade represents a 11.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Clemmer bought 10,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The stock was purchased at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the acquisition, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 20,890 shares of company stock valued at $239,532. 6.00% of the stock is owned by insiders.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.